| 1.47 -0.02 (-1.34%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.31  |
1-year : | 2.73 |
| Resists | First : | 1.98 |
Second : | 2.33 |
| Pivot price | 1.65 |
|||
| Supports | First : | 1.4 |
Second : | 1.17 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.74 |
| MA(100) : | 1.69 |
MA(250) : | 2.18 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 6.7 |
| RSI | RSI(14): 32.2 |
|||
| 52-week | High : | 3.61 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CMPX ] has closed above bottom band by 11.0%. Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.59 - 1.61 | 1.61 - 1.62 |
| Low: | 1.38 - 1.4 | 1.4 - 1.41 |
| Close: | 1.45 - 1.48 | 1.48 - 1.5 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Wed, 17 Apr 2024
Compass Therapeutics' (CMPX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Wed, 17 Apr 2024
Evaxion Biotech A/S (NASDAQ:EVAX) versus Compass Therapeutics (NASDAQ:CMPX) Head to Head Contrast - Defense World
Tue, 16 Apr 2024
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors - GlobeNewswire
Sun, 14 Apr 2024
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Down 13.8% in March - MarketBeat
Fri, 12 Apr 2024
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ... - GlobeNewswire
Fri, 12 Apr 2024
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 13.4 (%) |
| Held by Institutions | 62.8 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,840 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -4.46 |
| PEG Ratio | 0 |
| Price to Book value | 1.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|